Organizer

Luigi Naldini received his M.D. from the University of Turin, Italy, and his Ph.D. from the University of Rome. In the mid 90’s he moved to the Salk Institute in San Diego, USA, where he pioneered the development of lentiviral gene transfer vectors from HIV, which have become one of the most widely used tool in biomedical research. He then spent 2 years in the biotechnology industry in San Francisco, before moving back to academia in Turin. Since 2008 He has been the Director of the San Raffaele Telethon Institute for Gene Therapy of Milan (SR-Tiget), Italy, and Professor at the “Vita Salute” San Raffaele University in Milan. Throughout this time, he contributed to the safe and effective deployment of gene therapy for several inherited diseases and some types of cancer. His work also contributed to advance the use of artificial nucleases for targeted genome editing in cell and gene therapy. He is member of European Molecular Biology Organization (EMBO) and has been President of the European Society of Gene and Cell Therapy (ESGCT). He was awarded the Outstanding Achievement Award from the American Society of Gene and Cell Therapy (ASGCT) in 2014 and from the ESGCT in 2015, the Jimenez Diaz Prize in 2016, the Beutler Prize from the American Society of Hematology in 2017 and the 2019 Jeantet-Collen Prize for Translational Medicine. Has published 270 scientific papers cited >38,000 times; SCOPUS Author h-index : 93

« Go Back